XNK Therapeutics AB (“XNK”) recently announced the appointment of Dr. Anna-Karin Maltais as Chief Scientific Officer (CSO), effective October 17th. She will be a member of the company’s management team.
Anna-Karin Maltais, PhD, will be responsible for further developing and implementing XNK Therapeutics’ scientific strategy. She will lead a team responsible for research and innovation with focus on continuing the development of the company’s platform as well as improving the production processes and executing operational research plans.
Dr. Maltais received her PhD. in immunobiology and tumor immunology from Karolinska Institutet in 2006. Since then, she has been leading R&D activities and strategies within several organizations and has also had roles within corporate and business development. Most recently, she comes from Chiesi Farmaceutici S.p.A., a global company that develops and markets therapeutic solutions within a number of different therapeutic areas. At Chiesi, she was Head of CMC, Biotech Research and Product Development, Global Rare Diseases.
“At XNK, Anna-Karin’s experience in research and development will be invaluable as the company continues to grow into new indications,” said Johan Liwing, CEO of XNK Therapeutics. “We are very happy to have her join the team and are confident that she will make an immediate impact within the organization.”